1. Home
  2. QLGN vs OBLG Comparison

QLGN vs OBLG Comparison

Compare QLGN & OBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • OBLG
  • Stock Information
  • Founded
  • QLGN 1996
  • OBLG 2000
  • Country
  • QLGN United States
  • OBLG United States
  • Employees
  • QLGN 4
  • OBLG N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • OBLG Computer Software: Programming Data Processing
  • Sector
  • QLGN Health Care
  • OBLG Technology
  • Exchange
  • QLGN Nasdaq
  • OBLG Nasdaq
  • Market Cap
  • QLGN 2.7M
  • OBLG 3.8M
  • IPO Year
  • QLGN N/A
  • OBLG N/A
  • Fundamental
  • Price
  • QLGN $3.60
  • OBLG $3.77
  • Analyst Decision
  • QLGN
  • OBLG
  • Analyst Count
  • QLGN 0
  • OBLG 0
  • Target Price
  • QLGN N/A
  • OBLG N/A
  • AVG Volume (30 Days)
  • QLGN 226.0K
  • OBLG 61.2K
  • Earning Date
  • QLGN 11-29-2024
  • OBLG 11-07-2024
  • Dividend Yield
  • QLGN N/A
  • OBLG N/A
  • EPS Growth
  • QLGN N/A
  • OBLG N/A
  • EPS
  • QLGN N/A
  • OBLG N/A
  • Revenue
  • QLGN N/A
  • OBLG $2,759,000.00
  • Revenue This Year
  • QLGN N/A
  • OBLG N/A
  • Revenue Next Year
  • QLGN N/A
  • OBLG N/A
  • P/E Ratio
  • QLGN N/A
  • OBLG N/A
  • Revenue Growth
  • QLGN N/A
  • OBLG N/A
  • 52 Week Low
  • QLGN $3.55
  • OBLG $2.81
  • 52 Week High
  • QLGN $39.15
  • OBLG $14.80
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 25.42
  • OBLG 47.74
  • Support Level
  • QLGN $3.71
  • OBLG $3.70
  • Resistance Level
  • QLGN $4.56
  • OBLG $4.14
  • Average True Range (ATR)
  • QLGN 0.65
  • OBLG 0.26
  • MACD
  • QLGN -0.06
  • OBLG 0.04
  • Stochastic Oscillator
  • QLGN 2.08
  • OBLG 50.00

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About OBLG Oblong Inc.

Oblong Inc is a provider of patented multi-stream collaboration products and managed services for video collaboration and network solutions. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. Mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, real estate.

Share on Social Networks: